A Look At Amdocs (DOX) Valuation After Recent Share Price Weakness

Event context and recent stock performance

Amdocs (DOX) has drawn investor attention after a recent stretch of weak share performance, with the stock showing a 15% decline over the past month and a 10% decline over the past 3 months.

That pullback contrasts with the company’s latest reported annual figures, which show revenue of US$4.58b and net income of US$571.14m, supported by positive annual growth in both revenue and net income.

See our latest analysis for Amdocs.

Looking beyond the recent pullback, Amdocs’ share price is down 14.26% year to date and its 1 year total shareholder return of 19.81% decline points to fading momentum despite recent annual revenue and net income growth.

If this softer performance has you reassessing opportunities in the sector, it could be a good time to scan a broader set of 35 AI infrastructure stocks that might fit your portfolio better.

With Amdocs trading at US$68.73 and data suggesting a possible discount to some valuation estimates, the key question for investors is whether this pullback offers a buying opportunity or if the current share price already reflects expectations for future growth.

Most Popular Narrative: 26.7% Undervalued

The most followed narrative currently points to a fair value of $93.82 for Amdocs versus the last close at $68.73, setting up a sizeable valuation gap that hinges on how its cloud, AI and telecom offerings play out.

The accelerating adoption of cloud, automation, and AI/ML across telecom and media sectors is driving a multi-year wave of IT stack modernization, with Amdocs winning new large-scale modernization and migration deals in cloud, generative AI, and data services. This is expanding its total addressable market and supporting sustained topline revenue growth.

Customer conversions from generative AI proof-of-concepts (POCs) to production rollouts are increasing, creating a growing pipeline of incremental revenue and potential for future net margin expansion as Amdocs leads in deploying AI-powered platforms for automation and customer experience.

Read the complete narrative.

Want to see what kind of revenue path and margin profile needs to line up for that valuation gap to make sense? The narrative builds around moderate top line assumptions, a step up in profitability and a future earnings multiple that is lower than many large US IT peers. Curious which combination of growth, margin and discount rate brings that $93.82 figure into focus? The full story is in the detailed projections behind this narrative.

Result: Fair Value of $93.82 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on telco clients maintaining spending and on Amdocs scaling cloud and GenAI services. Any slowdown or project delays could challenge that undervalued story.

Find out about the key risks to this Amdocs narrative.

Next Steps

If the mixed sentiment here has you on the fence, it is worth moving quickly to review the numbers yourself and test the assumptions behind them. To round out your view, take a closer look at the 5 key rewards that investors are currently focusing on.

Looking for more investment ideas?

If Amdocs has sharpened your thinking, do not stop here. Use the Simply Wall St Screener to quickly surface other opportunities that could better match your goals.

• Target potential value opportunities by scanning our list of 47 high quality undervalued stocks that combine price appeal with underlying business strength.
• Strengthen your income focus by reviewing 14 dividend fortresses, where yields and business quality come together for investors who care about regular cash returns.
• Protect your capital by checking out 77 resilient stocks with low risk scores, highlighting companies with characteristics that may support more resilient performance through different market conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com